What is the 13F Pro Quality Score for ATRA?

13F Pro ranks Atara Biotherapeutics, Inc. (ATRA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ATRA's current score at https://13fpro.ai/company/ATRA (free sign-up required for the full ranking).

Where does 13F Pro source ATRA data?

All Atara Biotherapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Atara Biotherapeutics, Inc. files with the SEC under CIK 1604464. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ATRA in?

Atara Biotherapeutics, Inc. (ATRA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ATRA research updated on 13F Pro?

ATRA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Atara Biotherapeutics, Inc.(ATRA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1604464 ATRA stock profile & AI dashboard →

13F Pro Quality Score

8.1/100

Rank #2,936 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

0.3/100

Profitability

4.5/100

Balance Sheet

2.8/100

Earnings Quality

5.2/100

Free Cash Flow

3.3/100

Institutional Flow

93.6/100

Revenue Scale

1.5/100

Dilution Risk

18.9/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why ATRA Scores 8/100

exact factor attribution · 2026-09-11

ATRA's composite is driven by institutional flow, held back by revenue growth and scale. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Institutional flow

+2.2 pts

94th pct

Shareholder dilution

-1.6 pts

19th pct

Earnings growth

-2.3 pts

4th pct

Earnings quality

-4.5 pts

5th pct

Capital efficiency

-4.7 pts

3th pct

Profitability

-6.8 pts

5th pct

Free cash flow

-7.0 pts

3th pct

Scale

-7.3 pts

2th pct

Revenue growth

-9.9 pts

0th pct

Latest change (2026-08-12): 63 → 9 · ↓ Revenue growth 95→1; ↓ Profit margin 91→5

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in ATRA

Events flagged as statistical outliers against ATRA's own multi-year baseline — not fixed dollar thresholds.

Score shock2026-08-12
ATRA quality score dropped 54 points (63→9) on a new filing
View source filing →

ATRA Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Atara Biotherapeutics, Inc. (ATRA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ATRA at 8.1/100 on a 32-signal composite quality model, placing it at rank #2,936 of 2,962 stocks — the bottom half of the AI-ranked universe. ATRA scores in the top quartile across institutional flow (93.6). Areas of concern include revenue growth (0.3) and revenue scale (1.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 18.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Atara Biotherapeutics, Inc. reports quarterly revenue of $630.0K, net income of $-4.8M. Top institutional holders of ATRA by reported 13-F value include EcoR1 Capital, ADAGE CAPITAL PARTNERS GP, L.L.C., Point72 Asset Management, L.P., based on the most recent SEC filings. ATRA trades on the Nasdaq exchange and files with the SEC under CIK 1604464. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ATRA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Atara Biotherapeutics, Inc. directly from SEC EDGAR. Atara Biotherapeutics, Inc.'s 13F Pro composite quality score has ranged between 8 and 58 since 2024, currently 8.1 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about Atara Biotherapeutics, Inc.

Quirks, history, and lore behind ATRA — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in South San Francisco, the self-proclaimed biotech capital of the world.
2
The Numbers
A classic pre-revenue biotech — the company runs on capital raises and grants rather than product sales, with a market cap in the low hundreds of millions at its peak.
3
The History
Founded in the 2010s, it was built around a single bold scientific bet: that donor-derived T-cell therapies could fight diseases that conventional drugs could not.
4
The Secret
Its core platform targets Epstein-Barr virus — the ubiquitous pathogen linked to certain cancers and autoimmune diseases — a target most drugmakers have largely ignored.
5
The Lore
Its lead program pursued EBV-positive post-transplant lymphoproliferative disease, a rare and often fatal condition in immunocompromised patients — niche doesn't begin to cover it.
6
The Giveaway
The ticker ATRA is a clue in itself — this is Atara, the biotech named after a Hebrew word, betting everything on off-the-shelf T-cell medicine for EBV-driven illness.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$630.0K

Net Income

Q2 2026

$-4.8M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-6.3% YoY

$120.8MFY 2025

FY22 $63.6MFY23 $8.6MFY24 $128.9MFY25 $120.8M

Net Income

+138.3% YoY

$32.7MFY 2025

FY22 $-228.3MFY23 $-276.1MFY24 $-85.4MFY25 $32.7M

Operating Income

+143.0% YoY

$35.9MFY 2025

FY22 $-280.5MFY23 $-276.0MFY24 $-83.4MFY25 $35.9M

EPS (Diluted)

+122.5% YoY

$2.57FY 2025

FY22 $-2.24FY23 $-65.19FY24 $-11.41FY25 $2.57

Total Assets

-81.5% YoY

$20.2MFY 2025

FY22 $376.4MFY23 $165.5MFY24 $109.1MFY25 $20.2M

Op. Cash Flow

+25.9% YoY

$-50.9MFY 2025

FY22 $-270.4MFY23 $-193.0MFY24 $-68.7MFY25 $-50.9M

Free Cash Flow

+26.1% YoY

$-50.9MFY 2025

FY22 $-274.6MFY23 $-194.2MFY24 $-69.0MFY25 $-50.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$120.8M -6.3%	$128.9M +1404.0%	$8.6M -86.5%	$63.6M	—	—
Net Income	$32.7M +138.3%	$-85.4M +69.1%	$-276.1M -20.9%	$-228.3M +32.9%	$-340.1M -10.9%	$-306.6M
Operating Income	$35.9M +143.0%	$-83.4M +69.8%	$-276.0M +1.6%	$-280.5M +17.6%	$-340.5M -10.2%	$-309.1M
EPS (Diluted)	$2.57 +122.5%	$-11.41 +82.5%	$-65.19 -2810.3%	$-2.24 +38.3%	$-3.63 +12.5%	$-4.15
Total Assets	$20.2M -81.5%	$109.1M -34.1%	$165.5M -56.0%	$376.4M -19.6%	$468.1M -20.4%	$588.1M
Operating Cash Flow	$-50.9M +25.9%	$-68.7M +64.4%	$-193.0M +28.6%	$-270.4M -22.6%	$-220.5M -22.0%	$-180.8M
Free Cash Flow	$-50.9M +26.1%	$-69.0M +64.5%	$-194.2M +29.3%	$-274.6M -18.8%	$-231.1M -24.7%	$-185.3M

Get alerted when ATRA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Atara Biotherapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ATRA

EcoR1 Capital, LLC
$17.8M1,552,000 sh
ADAGE CAPITAL PARTNERS GP, L.L.C.
$9.8M850,000 sh
Point72 Asset Management, L.P.
$7.9M687,718 sh
Redmile Group, LLC
$5.1M441,701 sh
VANGUARD CAPITAL MANAGEMENT LLC
$2.8M247,047 sh
MACKENZIE FINANCIAL CORP
$2.7M233,249 sh
BlackRock, Inc.
$969.5K84,455 sh
GEODE CAPITAL MANAGEMENT, LLC
$862.9K75,128 sh
STALEY CAPITAL ADVISERS INC
$574.0K50,000 sh
VANGUARD FIDUCIARY TRUST CO
$494.1K43,036 sh

Fund	Value	Shares
EcoR1 Capital, LLC	$17.8M	1,552,000
ADAGE CAPITAL PARTNERS GP, L.L.C.	$9.8M	850,000
Point72 Asset Management, L.P.	$7.9M	687,718
Redmile Group, LLC	$5.1M	441,701
VANGUARD CAPITAL MANAGEMENT LLC	$2.8M	247,047
MACKENZIE FINANCIAL CORP	$2.7M	233,249
BlackRock, Inc.	$969.5K	84,455
GEODE CAPITAL MANAGEMENT, LLC	$862.9K	75,128
STALEY CAPITAL ADVISERS INC	$574.0K	50,000
VANGUARD FIDUCIARY TRUST CO	$494.1K	43,036

Companies Similar to ATRA

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

ZYME

Zymeworks Inc.

AI score

Very similar · 2 shared holders

EcoR1 Capital, LLC Redmile Group, LLC

ABSI

Absci Corp

AI score

Similar quality profile · 1 shared holders

Redmile Group, LLC

NRIX

Nurix Therapeutics, Inc.

AI score

Similar quality profile · 2 shared holders

EcoR1 Capital, LLC Redmile Group, LLC

STOK

Stoke Therapeutics, Inc.

AI score

Similar quality profile · 2 shared holders

EcoR1 Capital, LLC Redmile Group, LLC

CLDX

Celldex Therapeutics, Inc.

AI score

Similar quality profile · 1 shared holders

Redmile Group, LLC

RLAY

Relay Therapeutics, Inc.

AI score

Similar quality profile · 2 shared holders

EcoR1 Capital, LLC Raiffeisen Bank International AG

CRSP

CRISPR Therapeutics AG

AI score

Similar quality profile · 2 shared holders

EcoR1 Capital, LLC Raiffeisen Bank International AG

ZBIO

Zenas BioPharma, Inc.

AI score

Similar quality profile · 1 shared holders

EcoR1 Capital, LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ATRA on your watchlist

Track score changes the day Atara Biotherapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ATRA a good stock to buy?

13F Pro's AI-powered analysis of Atara Biotherapeutics, Inc. (ATRA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ATRA are available on the ATRA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ATRA is classified as a small company.

Which hedge funds own ATRA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ATRA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Atara Biotherapeutics, Inc.'s investment landscape.